Amendments to the Claims.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) An optical imaging contrast agent of formula I:

wherein:

V is one or more vector moieties with affinity for an abnormally expressed biological target associated with prostate cancer that target COX-2, urokinase receptor, epidermal growth factor receptor or vascular endothelial growth factor receptor (VEGFR);

L is a linker moiety or a bond; and

R is a reporter moiety comprising a cyanine dye.

- 2. (Currently amended) <u>The A contrast</u> agent as claimed in claim 1, wherein the molecular weight <u>of the agent</u> is below 14 000 Daltons.
- 3. (Canceled).
- 4. (Canceled).
- 5. (Canceled).
- 6. (Currently amended) <u>The A contrast</u>-agent as claimed in claim <u>1.3</u> wherein V <u>comprises is selected from</u> peptides, peptoid moieties, oligonucleotides, oligosaccharides, fat-related compounds <u>and or traditional organic drug-like small molecules</u>.

Appl. No. 10/582,842
Amdt. Dated February 22, 2011
Reply to Office action of August 26, 2010

7. (Canceled).

8. (Currently amended) A pharmaceutical composition for optical imaging of prostate cancer, comprising the a contrast agent as defined in claim 1, together with at least one pharmaceutically acceptable carrier or excipient.

9. (Canceled).

10. (Canceled).

11. (Canceled).

13. (Canceled).